Search

everythinglearnresearchcommunity

for

Search:↓

Personalized treatment considering atopic status and cytokine profiles may help in managing pediatric alopecia areata.

A man developed temporary hair loss after taking a cancer drug, which might indicate a better treatment response.

Many patients in the rheumatology clinic adjusted or stopped their medications due to side effects.

Sonidegib is effective and safe for treating advanced basal cell carcinoma, but biopsies are needed to confirm tumor clearance.

Abatacept may help some people with alopecia areata regrow hair.

Aggressive immunosuppressive treatment improved a woman's severe heart condition linked to autoimmune disease.

Effective management of side effects is crucial for safe use of sacituzumab govitecan in advanced breast cancer treatment.

Neutropenic patients show significant changes in immune cell types and lower neutrophil and natural killer cell percentages.

A man got six skin cancers within a year after a cell transplant for leukemia but was cancer-free 32 months later; skin checks are important post-transplant.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

Monoclonal antibodies are often linked to alopecia areata cases.

Patients and oncologists prioritize survival benefits, while payers focus on treatment costs.

Alopecia areata patients have more activated T cells in their blood, which may help in developing treatments.

The 2006 editorial concluded that immunotherapy was advancing with new drugs, focusing on specific biological therapies and convenient oral treatments, and highlighted the importance of partnerships and new regulations in the field.

Immunotherapy for cancer caused a patient to develop a condition affecting hormone production, requiring ongoing hormone replacement therapy.

Psoriasis or contact dermatitis can override alopecia areata, allowing hair growth.

Visceral leishmaniasis can mimic rheumatoid arthritis symptoms, especially in immunocompromised patients.

A woman with severe hair loss was successfully treated with the drug adalimumab.

Donors on most medications can donate certain blood products without waiting, except for specific drugs that need a waiting period.

The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.

Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.

Upadacitinib successfully regrew hair in a child with alopecia universalis and specific genetic mutations.

An elderly man with skin amyloidosis and abnormal blood proteins was monitored without finding widespread disease after 18 months.

Injecting recipient splenocytes into donors' thymus can prevent graft-versus-host disease.

A kidney transplant patient on cyclosporin experienced unexpected severe hair loss, which improved with treatment adjustments.

Nivolumab treatment led to hair regrowth in a man with metastatic melanoma and alopecia areata.

A five-month-old boy with Omenn syndrome successfully recovered after a stem cell transplant with reduced intensity conditioning.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

Thymus transplantation successfully restored immune function in infants with FOXN1 deficiency.

Skin and mucous membrane issues are common in kids after bone marrow transplants, so careful monitoring is crucial.